Development of a chimeric DNA-RNA hammerhead ribozyme targeting SARS virus.
Identifieur interne : 001910 ( PubMed/Corpus ); précédent : 001909; suivant : 001911Development of a chimeric DNA-RNA hammerhead ribozyme targeting SARS virus.
Auteurs : Akiko Fukushima ; Noboru Fukuda ; Yimu Lai ; Takahiro Ueno ; Mitsuhiko Moriyama ; Fumihiro Taguchi ; Akifumi Iguchi ; Kazushi Shimizu ; Kazumichi KurodaSource :
- Intervirology [ 1423-0100 ] ; 2009.
English descriptors
- KwdEn :
- Animals, Antiviral Agents (pharmacology), Base Sequence, Cell Line, Mice, Models, Molecular, Molecular Sequence Data, Murine hepatitis virus (drug effects), Murine hepatitis virus (genetics), Murine hepatitis virus (physiology), RNA Stability, RNA, Catalytic (genetics), RNA, Catalytic (pharmacology), RNA, Viral (metabolism), SARS Virus (drug effects), SARS Virus (genetics), SARS Virus (physiology), Virus Replication (drug effects).
- MESH :
- chemical , genetics : RNA, Catalytic.
- chemical , metabolism : RNA, Viral.
- chemical , pharmacology : Antiviral Agents, RNA, Catalytic.
- drug effects : Murine hepatitis virus, SARS Virus, Virus Replication.
- genetics : Murine hepatitis virus, SARS Virus.
- physiology : Murine hepatitis virus, SARS Virus.
- Animals, Base Sequence, Cell Line, Mice, Models, Molecular, Molecular Sequence Data, RNA Stability.
Abstract
Severe acute respiratory syndrome (SARS) is a severe pulmonary infectious disease caused by a novel coronavirus. To develop an effective and specific medicine targeting the SARS-coronavirus (CoV), a chimeric DNA-RNA hammerhead ribozyme was designed and synthesized using a sequence homologous with the mouse hepatitis virus (MHV).
DOI: 10.1159/000215946
PubMed: 19420961
Links to Exploration step
pubmed:19420961Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Development of a chimeric DNA-RNA hammerhead ribozyme targeting SARS virus.</title><author><name sortKey="Fukushima, Akiko" sort="Fukushima, Akiko" uniqKey="Fukushima A" first="Akiko" last="Fukushima">Akiko Fukushima</name><affiliation><nlm:affiliation>Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Fukuda, Noboru" sort="Fukuda, Noboru" uniqKey="Fukuda N" first="Noboru" last="Fukuda">Noboru Fukuda</name></author><author><name sortKey="Lai, Yimu" sort="Lai, Yimu" uniqKey="Lai Y" first="Yimu" last="Lai">Yimu Lai</name></author><author><name sortKey="Ueno, Takahiro" sort="Ueno, Takahiro" uniqKey="Ueno T" first="Takahiro" last="Ueno">Takahiro Ueno</name></author><author><name sortKey="Moriyama, Mitsuhiko" sort="Moriyama, Mitsuhiko" uniqKey="Moriyama M" first="Mitsuhiko" last="Moriyama">Mitsuhiko Moriyama</name></author><author><name sortKey="Taguchi, Fumihiro" sort="Taguchi, Fumihiro" uniqKey="Taguchi F" first="Fumihiro" last="Taguchi">Fumihiro Taguchi</name></author><author><name sortKey="Iguchi, Akifumi" sort="Iguchi, Akifumi" uniqKey="Iguchi A" first="Akifumi" last="Iguchi">Akifumi Iguchi</name></author><author><name sortKey="Shimizu, Kazushi" sort="Shimizu, Kazushi" uniqKey="Shimizu K" first="Kazushi" last="Shimizu">Kazushi Shimizu</name></author><author><name sortKey="Kuroda, Kazumichi" sort="Kuroda, Kazumichi" uniqKey="Kuroda K" first="Kazumichi" last="Kuroda">Kazumichi Kuroda</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:19420961</idno><idno type="pmid">19420961</idno><idno type="doi">10.1159/000215946</idno><idno type="wicri:Area/PubMed/Corpus">001910</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001910</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Development of a chimeric DNA-RNA hammerhead ribozyme targeting SARS virus.</title><author><name sortKey="Fukushima, Akiko" sort="Fukushima, Akiko" uniqKey="Fukushima A" first="Akiko" last="Fukushima">Akiko Fukushima</name><affiliation><nlm:affiliation>Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Fukuda, Noboru" sort="Fukuda, Noboru" uniqKey="Fukuda N" first="Noboru" last="Fukuda">Noboru Fukuda</name></author><author><name sortKey="Lai, Yimu" sort="Lai, Yimu" uniqKey="Lai Y" first="Yimu" last="Lai">Yimu Lai</name></author><author><name sortKey="Ueno, Takahiro" sort="Ueno, Takahiro" uniqKey="Ueno T" first="Takahiro" last="Ueno">Takahiro Ueno</name></author><author><name sortKey="Moriyama, Mitsuhiko" sort="Moriyama, Mitsuhiko" uniqKey="Moriyama M" first="Mitsuhiko" last="Moriyama">Mitsuhiko Moriyama</name></author><author><name sortKey="Taguchi, Fumihiro" sort="Taguchi, Fumihiro" uniqKey="Taguchi F" first="Fumihiro" last="Taguchi">Fumihiro Taguchi</name></author><author><name sortKey="Iguchi, Akifumi" sort="Iguchi, Akifumi" uniqKey="Iguchi A" first="Akifumi" last="Iguchi">Akifumi Iguchi</name></author><author><name sortKey="Shimizu, Kazushi" sort="Shimizu, Kazushi" uniqKey="Shimizu K" first="Kazushi" last="Shimizu">Kazushi Shimizu</name></author><author><name sortKey="Kuroda, Kazumichi" sort="Kuroda, Kazumichi" uniqKey="Kuroda K" first="Kazumichi" last="Kuroda">Kazumichi Kuroda</name></author></analytic><series><title level="j">Intervirology</title><idno type="eISSN">1423-0100</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiviral Agents (pharmacology)</term><term>Base Sequence</term><term>Cell Line</term><term>Mice</term><term>Models, Molecular</term><term>Molecular Sequence Data</term><term>Murine hepatitis virus (drug effects)</term><term>Murine hepatitis virus (genetics)</term><term>Murine hepatitis virus (physiology)</term><term>RNA Stability</term><term>RNA, Catalytic (genetics)</term><term>RNA, Catalytic (pharmacology)</term><term>RNA, Viral (metabolism)</term><term>SARS Virus (drug effects)</term><term>SARS Virus (genetics)</term><term>SARS Virus (physiology)</term><term>Virus Replication (drug effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>RNA, Catalytic</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>RNA, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term><term>RNA, Catalytic</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Murine hepatitis virus</term><term>SARS Virus</term><term>Virus Replication</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Murine hepatitis virus</term><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Murine hepatitis virus</term><term>SARS Virus</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Base Sequence</term><term>Cell Line</term><term>Mice</term><term>Models, Molecular</term><term>Molecular Sequence Data</term><term>RNA Stability</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) is a severe pulmonary infectious disease caused by a novel coronavirus. To develop an effective and specific medicine targeting the SARS-coronavirus (CoV), a chimeric DNA-RNA hammerhead ribozyme was designed and synthesized using a sequence homologous with the mouse hepatitis virus (MHV).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19420961</PMID><DateCompleted><Year>2009</Year><Month>07</Month><Day>02</Day></DateCompleted><DateRevised><Year>2009</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1423-0100</ISSN><JournalIssue CitedMedium="Internet"><Volume>52</Volume><Issue>2</Issue><PubDate><Year>2009</Year></PubDate></JournalIssue><Title>Intervirology</Title><ISOAbbreviation>Intervirology</ISOAbbreviation></Journal><ArticleTitle>Development of a chimeric DNA-RNA hammerhead ribozyme targeting SARS virus.</ArticleTitle><Pagination><MedlinePgn>92-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1159/000215946</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Severe acute respiratory syndrome (SARS) is a severe pulmonary infectious disease caused by a novel coronavirus. To develop an effective and specific medicine targeting the SARS-coronavirus (CoV), a chimeric DNA-RNA hammerhead ribozyme was designed and synthesized using a sequence homologous with the mouse hepatitis virus (MHV).</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Chimeric DNA-RNA hammerhead ribozyme targeting MHV and SARS-CoV were designed and synthesized.To confirm its activity, in vitro cleavage reactions were performed with the synthesized ribozyme. Effects of the chimeric ribozyme were evaluated on multiplication of MHV. Effects of the chimeric ribozyme on expression of SARS-CoV were evaluated in cultured 3T3 cells.</AbstractText><AbstractText Label="RESULT" NlmCategory="RESULTS">The synthetic ribozyme cleaved the synthetic target MHV and SARS-CoV RNA into fragments of predicted length. The chimeric DNA-RNA hammerhead ribozyme targeting SARS-CoV significantly inhibited multiplication of MHV in DBT cells by about 60%. The chimeric DNA-RNA hammerhead ribozyme targeting SARS-CoV significantly inhibited the expression of SARS-CoV RNA in 3T3 cells transfected with the recombinant plasmid. The chimeric DNA-RNA ribozyme targeting SARS-CoV significantly inhibited MHV viral activity and expression of recombinant SARS RNA in vitro.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These findings indicate that the synthetic chimeric DNA-RNA ribozyme could provide a feasible treatment for SARS.</AbstractText><CopyrightInformation>Copyright (c) 2009 S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fukushima</LastName><ForeName>Akiko</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fukuda</LastName><ForeName>Noboru</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Yimu</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Ueno</LastName><ForeName>Takahiro</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Moriyama</LastName><ForeName>Mitsuhiko</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Taguchi</LastName><ForeName>Fumihiro</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Iguchi</LastName><ForeName>Akifumi</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Shimizu</LastName><ForeName>Kazushi</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Kuroda</LastName><ForeName>Kazumichi</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>05</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Intervirology</MedlineTA><NlmUniqueID>0364265</NlmUniqueID><ISSNLinking>0300-5526</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016337">RNA, Catalytic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C427204">hammerhead ribozyme</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006517" MajorTopicYN="N">Murine hepatitis virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020871" MajorTopicYN="N">RNA Stability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016337" MajorTopicYN="N">RNA, Catalytic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>02</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>5</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>5</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>7</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19420961</ArticleId><ArticleId IdType="pii">000215946</ArticleId><ArticleId IdType="doi">10.1159/000215946</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001910 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001910 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:19420961
|texte= Development of a chimeric DNA-RNA hammerhead ribozyme targeting SARS virus.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:19420961" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |